A Study of NP-011 in Healthy Volunteers

NCT05387499 | Completed Phase 1 DMC

• 1 other identifier: NP-011-001
• Study Type: interventional
• Target: 64
• Locations: 1 country
• Sites: 1

Brief Summary

This is a Phase 1, randomised, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study to evaluate the safety, tolerability, and pharmacokinetic of NP-011 in healthy volunteers.

Conditions

Myocardial Infarction

Outcome Measures

Primary Outcomes (1)

• The safety and tolerability of single and multiple doses of NP-011 through the incidence, nature and severity of adverse events

  Adverse Events will be coded using the most current version of the MedDRA®

  Screening to end of the follow up period; up to 36 and 56 days for Single Ascending Dose and Multiple Ascending Dose

Secondary Outcomes (4)

• To characterize the plasma pharmacokinetics (PK) of NP-011 in healthy volunteers

  Screening to end of the follow up period; up to 36 and 56 days for Single Ascending Dose and Multiple Ascending Dose

• To characterize the plasma pharmacokinetics (PK) of NP-011 in healthy volunteers

  Screening to end of the follow up period; up to 36 and 56 days for Single Ascending Dose and Multiple Ascending Dose

• To characterize the plasma pharmacokinetics (PK) of NP-011 in healthy volunteers

  Screening to end of the follow up period; up to 36 and 56 days for Single Ascending Dose and Multiple Ascending Dose

• To characterize the immunogenicity of NP-011 in healthy volunteers by assessing the development of anti-drug-antibodies (ADA) through change from baseline in neutralizing antibody titers for NP-011 after single and multiple doses.

  Screening to end of the follow up period; up to 36 and 56 days for Single Ascending Dose and Multiple Ascending Dose

Study Arms (3)

Single Ascending Dose Phase

EXPERIMENTAL

Drug: NP-011 Dosage: 250μg, 500μg, 1000μg, 2000μg, 4000μg Dosage Form: Liquid for IV injection Route of Administration: Intravenous

Drug: NP-011 (Single Ascending Dose Phase)

Multiple Ascending Dose Phase

EXPERIMENTAL

Drug: NP-011 Dosage: 1000μg, 2000μg, 4000μg Dosage Form: Liquid for IV injection Route of Administration: Intravenous

Drug: NP-011 (Multiple Ascending Dose Phase)

Placebo

PLACEBO COMPARATOR

Dosage Form: Liquid for IV injection Route of Administration: Intravenous

Other: NP-011 (Placebo)

Interventions

NP-011 (Single Ascending Dose Phase) DRUG

The participants will receive assigned single dose of NP-011 after a minimum 8 hour fast on Day 1

Single Ascending Dose Phase

NP-011 (Multiple Ascending Dose Phase) DRUG

The participants will receive assigned dose of NP-011 after a minimum 8 hour fast once daily for 7 days

Multiple Ascending Dose Phase

NP-011 (Placebo) OTHER

The participants will receive single dose of NP-011 after a minimum 8 hour fast on Day 1 in Single Ascending Dose part and will receive once daily for 7 days after a minimum 8 hour fast in Multiple Ascending dose part of the study

Placebo

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Normal healthy volunteers with an age of 18 to 65 years inclusive at the time of informed consent.
• Participants must be in good general health, in the opinion of the Investigator, with no significant medical history (ie, history of childhood asthma \[resolved\] is acceptable; history of depression \[non-hospitalised, medicated\] or migraines is not acceptable), and no clinically significant abnormalities on physical examination at Screening and/or before administration of the initial dose of IP.
• Participants must have documented evidence of receipt of licensed COVID-19 vaccinations as per the current Australian Technical Advisory Group on Immunisation (ATAGI) guidelines and be fully vaccinated as per local guidelines.
• Participants must have a BMI between \> 18.0 and \< 32.0 kg/m2 at Screening.
• Participants must have clinical laboratory values within normal range as specified by the testing laboratory, unless deemed not clinically significant by the Investigator or delegate. A single repeat test can be performed for clinically significant abnormal values, at the discretion of the Investigator.
• Participants must be a non-smoker and must not have used any tobacco products within 2 months prior to Screening, or if a smoker, they must smoke no more than 2 cigarettes or equivalent per week.
• Participants must have no relevant dietary restrictions (restrictions that would prevent consumption of the standard meals to be provided), and be willing to consume standard meals provided.
• Females must be non-pregnant and non-lactating, and must use an acceptable, highly effective double contraception from Screening until 30 days after last dose of IP, including the follow-up period. Double contraception is defined as a condom AND one other form of the following:
• Established hormonal contraception (with approved oral contraceptive pills \[OCPs\], long-acting implantable hormones, injectable hormones);
• A vaginal ring or an intrauterine device (IUD);
• Documented evidence of surgical sterilisation at least 6 months prior to Screening (eg, tubal occlusion, hysterectomy, bilateral salpingectomy, or bilateral oophorectomy for women or vasectomy for men, provided the male partner is a sole partner).
• Women not of childbearing potential must be post-menopausal for ≥ 12 months. Post-menopausal status will be confirmed through testing of follicle-stimulating hormone (FSH) levels ≥ 40 IU/L at Screening for amenorrhoeic female participants. Females who are abstinent from heterosexual intercourse will also be eligible.
• Periodic abstinence (eg, calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not considered highly effective methods of birth control. Participant complete abstinence for the duration of the study and for 1 month after the last study treatment is acceptable.
• Female participants who are in exclusively same-sex relationships are not required to use contraception.
• Woman of childbearing potential (WOCBP) must have a negative pregnancy test at Screening and Day 1 and be willing to have additional pregnancy tests as required throughout the study.

You may not qualify if:

• Use of any IP or investigational medicinal device within 30 days prior to treatment, or 5 half-lives of the product, whichever is the longest.
• Prior or ongoing medical conditions, medical history, physical findings, or laboratory abnormality that, in the Investigator's opinion, could adversely affect the safety of the participant or confound treatment assessment.
• Allergy or hypersensitivity to the IP or any of its constituents.
• History of allergic or anaphylactic reactions that are considered severe in the opinion of the Investigator (with the allowance of well-managed allergies such as allergic rhinitis, eczema, stinging insect allergies, and pollen allergies).
• Any history of cardiac disease.
• Abnormal ECG findings at Screening that are considered by the Investigator to be clinically significant.
• Use of or anticipated use of any prescription drugs (other than hormonal contraception; OCPs, long-acting implantable hormones, injectable hormones, a vaginal ring, or an IUD), over-the-counter (OTC) medication, herbal remedies, supplements, or vitamins 2 weeks prior to dosing and during course of study without prior approval of the Investigator and MM. Simple analgesics (paracetamol, nonsteroidal anti-inflammatory drugs \[NSAIDs\]) are permitted at 1 or 2 therapeutic doses per week at the discretion of the Investigator.
• Pregnant or lactating at Screening or planning to become pregnant (self or partner) at any time during the study, including the follow-up period.
• Presence of any underlying physical or psychological medical condition that, in the opinion of the Investigator, would make it unlikely that the participant will comply with the protocol or complete the study per protocol.
• Blood donation or significant blood loss within 60 days prior to the first IP administration.
• Plasma donation within 7 days prior to the first IP administration.
• Fever (body temperature \> 38°C) or symptomatic viral or bacterial infection within 2 weeks prior to Screening.
• History of malignancy, except for non-melanoma skin cancer, excised more than 2 years ago and cervical intraepithelial neoplasia that has been successfully cured more than 5 years prior to Screening.
• History or presence of a condition associated with significant immunosuppression (significant in the opinion of the Investigator).
• History of life-threatening infection (eg, meningitis).

Sponsors & Collaborators

• Nexel Co., Ltd.: lead
• Novotech (Australia) Pty Limited: collaborator

Study Sites (1)

CMAX Clinical Research Pty Ltd

Adelaide, South Australia, 5063, Australia

Location

MeSH Terms

Conditions

Myocardial Infarction

Condition Hierarchy (Ancestors)

Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Vascular Diseases; Infarction; Ischemia; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Necrosis

Study Officials

• Jessica Gehlert

  CMAX Clinical Research Pty Ltd

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 4, 2022
• First Posted: May 24, 2022
• Study Start: June 10, 2022
• Primary Completion: March 7, 2023
• Study Completion: May 26, 2023
• Last Updated: August 3, 2023

Record last verified: 2023-03

Data Sharing

• IPD Sharing: Will not share

Locations

AU (1)